Nalbuphine as an Adjuvant to Intravenous Regional Anesthesia

A

Assiut University

Status

Completed

Conditions

Postoperative Pain

Treatments

Drug: Lidocaine
Drug: Nalbuphine

Study type

Interventional

Funder types

Other

Identifiers

NCT02678585
000087161

Details and patient eligibility

About

The effect of addition of nalbuphine to lidocaine in intravenous regional anesthesia

Enrollment

106 patients

Sex

All

Ages

20 to 50 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • adult patients
  • American Society of Anesthesiologists (ASA) physical status I-II
  • age between 20 and 50 years old
  • scheduled for elective unilateral short hand surgery

Exclusion criteria

  • allergy to study medications
  • body mass index > 35 kg/m2
  • patients with sickle cell disease or Reynaud disease
  • patient refusal

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

106 participants in 2 patient groups

Nalbuphine
Active Comparator group
Description:
53 patients received intravenous regional lidocaine plus Nalbuphine
Treatment:
Drug: Nalbuphine
Control group
Other group
Description:
53 patients received intravenous regional lidocaine
Treatment:
Drug: Lidocaine

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems